Show simple item record

dc.contributor.authorWischik, Claude M
dc.contributor.authorStaff, Roger T
dc.contributor.authorWischik, Damon J
dc.contributor.authorBentham, Peter
dc.contributor.authorMurray, Alison D
dc.contributor.authorStorey, John M D
dc.contributor.authorKook, Karin A
dc.contributor.authorHarrington, Charles R
dc.date.accessioned2015-01-27T10:04:01Z
dc.date.available2015-01-27T10:04:01Z
dc.date.issued2015-01-22
dc.identifier.citationWischik , C M , Staff , R T , Wischik , D J , Bentham , P , Murray , A D , Storey , J M D , Kook , K A & Harrington , C R 2015 , ' Tau Aggregation Inhibitor Therapy : An Exploratory Phase 2 Study in Mild or Moderate Alzheimer's Disease ' , Journal of Alzheimer's Disease , vol. 44 , no. 2 , pp. 705-720 . https://doi.org/10.3233/JAD-142874en
dc.identifier.issn1387-2877
dc.identifier.otherPURE: 46126219
dc.identifier.otherPURE UUID: 2de5d671-226c-45f9-8e8d-713ec5683bfe
dc.identifier.otherPubMed: 25550228
dc.identifier.otherScopus: 84921531217
dc.identifier.otherORCID: /0000-0002-5261-5467/work/73579154
dc.identifier.otherORCID: /0000-0003-4915-4847/work/44018599
dc.identifier.urihttp://hdl.handle.net/2164/4205
dc.descriptionACKNOWLEDGMENTS We thank patients and their caregivers for their participation in the study and are indebted to all the investigators involved in the study, particularly Drs. Douglas Fowlie and Donald Mowat for their helpful contributions to the clinical execution of the study in Scotland. We thank Sharon Eastwood, Parexel, for assistance in preparing initial drafts of the manuscript. We acknowledge constructive comments provided by Professors G. Wilcock and S. Gauthier on drafts of the article. CMW, CRH, and JMDS are officers of, and hold beneficial interests in, TauRx Therapeutics. RTS, PB, KK, and DJW are paid consultants to TauRx Therapeutics. The study was financed entirely by TauRx Therapeuticsen
dc.format.extent16
dc.language.isoeng
dc.relation.ispartofJournal of Alzheimer's Diseaseen
dc.rightsThis is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/3.0/en
dc.subjectAlzheimer's diseaseen
dc.subjectcontrolled clinical trialen
dc.subjectintervention studiesen
dc.subjectmethylthioniniumen
dc.subjectsafetyen
dc.subjecttau proteinen
dc.subjectR Medicineen
dc.subjectSupplementary Dataen
dc.subject.lccRen
dc.titleTau Aggregation Inhibitor Therapy : An Exploratory Phase 2 Study in Mild or Moderate Alzheimer's Diseaseen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Medical Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Applied Medicineen
dc.contributor.institutionUniversity of Aberdeen.Data Safe Havenen
dc.contributor.institutionUniversity of Aberdeen.Chemistryen
dc.contributor.institutionUniversity of Aberdeen.Institute of Medical Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Chemistry (Research Theme)en
dc.contributor.institutionUniversity of Aberdeen.Clinical Medicineen
dc.contributor.institutionUniversity of Aberdeen.Aberdeen Biomedical Imaging Centreen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.3233/JAD-142874
dc.identifier.vol44en
dc.identifier.iss2en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record